Le Lézard
Classified in: Health
Subjects: NPT, VET, CSR

Campaign Launched to Support Veterans Living with Ringing in The Ears


PORTLAND, Ore., Nov. 9, 2018 /PRNewswire/ -- Otoharmonics Corporation, makers of the Levo System for tinnitus, announces the Otoharmonics Veterans Assistance Program to recognize and honor those who have serviced in the U.S. Military. Starting this Veteran's Day, active duty and retired veterans may be nominated to receive a reduced-cost Levo System to offset the out-of-pocket expenses associated with tinnitus therapy.

"This initiative continues Otoharmonics' long-standing dedication to expand and improve care for service men and women," said Michael Baker, CEO and President of Otoharmonics. "We are thankful for the VA-sponsored clinics that currently offer the Levo System and look forward to seeing access to evidence-based therapy with the Levo System expand nationwide."

Open to all active or retired members of the United States Military, qualified veterans can be nominated for the Otoharmonics Veterans Assistance Program by visiting Otoharmonics.com/OVAP. The Levo System is available by prescription only from a qualified healthcare provider. 

Tinnitus is the number one service-related disability among U.S. veterans, according to the American Tinnitus Association. An often-overlooked outcome of active duty, tinnitus is typically a result of exposure to loud noise. Whether it's from a high noise environment such as flight, use of heavy machinery, or being near severe and sudden explosives, the effects of tinnitus can be long-lasting. Left untreated, symptoms may increase over time and significantly impact quality of life.

Compatible with the Clinical Practice Guidelines for Tinnitus published by the American Academy of Otolaryngologists and the VA's Progressive Tinnitus Management Program, the Levo System offers sound therapy that has been shown to reduce the level of tinnitus intensity and improve quality of life in several published peer-reviewed studies, including a randomized controlled study by the National Center for Rehabilitative Auditory Research at the VA Portland Health Care System.   

About Otoharmonics Corporation
Otoharmonics Corporation is a privately held company with headquarters in Portland, Oregon USA.  An international team of world?class neuroscientists, clinicians, business professionals and patients, Otoharmonics has developed the Levo System for tinnitus management. Specifically designed for use during sleep, the Levo system utilizes Apple mobile digital devices to offer user-friendly custom sound therapy based on the specific needs of the individual. To learn more visit http://otoharmonics.com or call 503.336.9906.

Otoharmonics and Levo are registered trademarks of Otoharmonics Corporation.

Contact:
Brenda Edin
Otoharmonics Corporation
[email protected]
503-336-9906

SOURCE Otoharmonics


These press releases may also interest you

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...



News published on and distributed by: